Phathom Pharmaceuticals, Inc. Capex per Share

Capex per Share of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Capex per Share growth rates and interactive chart. Capex per share refers to the total amount of capital expenditures paid in a period divided by the weighted average number of shares outstanding. If a company has capex of $100 million and 10 million shares outstanding, capex per share is $10.


Highlights and Quick Summary

  • Capex per Share for the quarter ending September 29, 2021 was -0.0 (a -66.67% decrease compared to previous quarter)
  • Year-over-year quarterly Capex per Share decreased by -88.89%
  • Annual Capex per Share for 2020 was -0.03 (a -96.93% decrease from previous year)
  • Annual Capex per Share for 2019 was -1.02 (a -Infinity% decrease from previous year)
  • Twelve month Capex per Share ending September 29, 2021 was -0.01 (a -33.8% decrease compared to previous quarter)
  • Twelve month trailing Capex per Share decreased by -69.18% year-over-year
Trailing Capex per Share for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
-0.01 -0.01 -0.01 -0.03
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Capex per Share of Phathom Pharmaceuticals, Inc.

Most recent Capex per Shareof PHAT including historical data for past 10 years.

Interactive Chart of Capex per Share of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Capex per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -0.0 -0.0 -0.0
2020 -0.0 -0.01 -0.0 -0.02 -0.03
2019 -0.01 -0.0 -3.75 0.0 -1.02
2018 0.0 0.0 0.0

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.